Halozyme Therapeutics Inc.

NASDAQ:HALO   4:00:00 PM EDT
40.68
-0.05 (-0.12%)
7:57:22 PM EDT: $40.86 +0.18 (+0.44%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)5.17B
Current PE18.36
Forward PE 11.56
2yr Forward PE 9.16
See more stats
Estimates Current Quarter
Revenue$212.15 Million
Adjusted EPS$0.74
See more estimates
10-Day MA$40.54
50-Day MA$37.92
200-Day MA$38.45
See more pivots

Halozyme Therapeutics Inc. Stock, NASDAQ:HALO

12390 El Camino Real, San Diego, California 92130
United States of America
Phone: +1.858.794.8889
Number of Employees: 373

Description

Halozyme Therapeutics, Inc. is a biopharmaceutical technology platform company. It engages in developing, manufacturing, and commercializing drug-device combination products using advanced auto-injector technology that are designed to provide commercial or functional advantages such as improved convenience and tolerability, and enhanced patient comfort and adherence. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.